SOMERSET, N.J. – December 3, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it is investing $10 million in isolator capabilities at its sites in Malvern, Pennsylvania and Dartford, U.K., to expand its micronization capabilities for highly potent drug compounds.

The investment will allow flexible jet milling operations to be carried out at both sites under containment to a working occupational exposure limit (OEL) of 0.05 micrograms per cubic meter, enabling micronization of potent and highly potent compounds, at less than 10 and less than 1 microgram per cubic meter respectively. Additionally, the capability to operate under an inert nitrogen environment offers enhanced manufacturing safety, eliminates the risk of dust explosion for compounds with low minimum ignition energy (MIE) values, and enables the processing of humidity, light and oxygen-sensitive materials. Work is underway at both facilities, with installation and validation activities likely to be completed by mid-2021.

At Dartford, the isolator will encompass a K-Tron gravimetric feeder with KT35 hopper and feed screws, suitable for 8-inch and 12-inch jet mills. The DEC Group designed system will be fully automated and allow product and waste to be collected within a safe, controlled environment. At the Malvern facility, the nine-chamber isolator will be housed within a new extension at the site, and will be one of the biggest isolators installed in the United States. The multi-chamber design, undertaken by FPS Architects & Engineers Limited, offers superior ergonomics and is optimized to significantly reduce cleaning and maintenance time.

“Catalent offers multiple tools and technologies to drug innovators to improve the characteristics and efficacy of new molecules, and micronization is an important engineering step for many materials to help improve the solubility of oral drugs and optimize inhaled therapies,” commented James Walter, Vice President Operations, Oral and Specialty Delivery at Catalent. “This investment allows us to ensure that access to this technology is not limited, as we see the development of highly potent molecules becoming more prevalent in the small molecule R&D pipeline against a number of disease targets.”

The Dartford and Malvern sites offer world-leading expertise and experience in particle size reduction capabilities including micronization, jet milling, mechanical milling, cryogenic milling and associated analytical services, and work alongside Catalent’s network of commercial-scale facilities. The company recently announced the launch of its OneXpress™ solution to integrate and accelerate a program’s transition from early-phase development to commercial-ready manufacturing by leveraging its phase-appropriate scale, technologies, extensive oral dose form network and expertise to reduce risk, complexity and cost between phases.

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

MORE PRODUCTS. BETTER TREATMENTS. RELIABLY SUPPLIED.™